Dr. Nishi Suryavanshi Receives Award from ACTG Network

Date: 01/07/2022

Congratulations, Nishi Suryavanshi, recipient of ACTG’s Tuberculosis Transformative Science Group Special Contributions Award.

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Purpose: The C-TRIUMPH study has identified 20 household contacts (HHC), who have progressed to active TB from its HHCs cohort...

Study Description A5384 is a trial for people who have or might have tuberculous meningitis (TBM). TBM is an infectious disease...

The study is being done to: test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...